Chul Kim (@chulkimMD) ranks #12 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 28 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HARMONi-6, DESTINY-Lung04, CROWN. CMS Open Payments lists $64,694 in 2025 general payments.
At a Glance
- 15 posts naming a trial in 2026
- 12 trials discussed by name
- Lung Cancer: US #12, Global #26 · 28 physicians engaged
- Presented at WCLC 2026 in 2026
- CMS Open Payments lists $64,694 in 2025 general payments.
This Month
What Chul Kim has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Chul Kim
Physicians who reposted Chul Kim’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #12 | #26 | 28 | 38 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Chul Kim presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · Plenary (PL03.03)PAPILLON: First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall SurvivalPAPILLON trial profile → · Source: @HHorinouchi on X ↗
What Colleagues Are Saying About Chul Kim
2026 posts by fellow physicians that mention @chulkimMD, quoted word for word.
🆙#WCLC26 #LCSM Plenary Session 🔥PAPILLON: First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival 🎙️ @chulkimMD 🔢PL03.03 ☑️NCT04538664 🔗 https://t.co/mYsNwaWQUZ @OncoAlert @Larvol @IASLC @EGFRResisters @Exon20Group https://t.co/1Q6iRvY46I https://t.co/poufzTii55
What does @chulkimMD of @MedStarHealth think are the most impactful studies presented at #WCLC26? on this #HealthcareUnfiltered EXPRESS, Dr. Kim summarizes what you need to know in 16 minutes. From Maverick to ADAURA and more. Check it out - streaming everywhere. https://t.co/lk9iR9TaS7
Dr. @chulkimMD from @LombardiCancer presents final OS analysis on phase III PAPILLON trial: 1L amivantamab + chemo vs chemo alone for EGFR exon 20 insertion NSCLC at #WCLC26. Importantly, this trial permitted crossover for patients randomized to chemotherapy alone and 76% who progressed did crossover to ami. This has a major impact on OS but really is the right thing to do. The OS here was the longest reported to date for EGFRex20 at 34.3m vs 27.9m (HR 0.87, ns). IPCW adjusted survival to account for crossover showed an OS HR of 0.57.
Phenomenal presentation by @chulkimMD on PAPILLON OS @ #WCLC26! ⭐️OS impressive improvement, 34.3 mo, (notable 76% crossover), toxicities remain challenging. Thankfully a growing field, offering this and additional options to our patients. https://t.co/eJ4eELxBR7
#WCLC26 Presidential Symposium Day 2 🔥#PAPILLON: First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival update 🎙️ @chulkimMD 🎯 mOS: 34.3 mos amivantamab+chemo vs 27.9 mos with chemo ( HR 0.87)- crossover adjusted HR 0.57 ⚡️76% crossover 👉🏽current 1st line option in the US- soon to compete w new oral agents. @Exon20Group @EGFRResisters #lcsm
🫁 Plenary session on EGFR Exon 20 ins #NSCLC data at #WCLC26 with abstract discussion by @LudaBazhenovaMD including comparing data from WU-KONG 28 🔥 📊 Presented by @danieltanmd REZILIENT3 (zipalertinib+chemo): PFS 14.5 vs 8.5 mo, HR 0.50, P=0.00015. OS immature (HR 0.72, P=0.11), 64% crossover 📊 Presented by @chulkimMD PAPILLON (ami+chemo): final OS 34.3 vs 27.9 mo, HR 0.87 (P=0.307). After IPCW crossover adjustment: HR 0.57, nominal P=0.003. 76% of chemo pts crossed over to amivantamab
Trials Chul Kim Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HARMONi-6 | 3 | #18 of 74 | May 31, 2026 |
| DESTINY-Lung04 | 2 | #10 of 37 | Oct 10, 2026 |
| CROWN | 2 | #15 of 36 | Oct 10, 2026 |
| KEYNOTE-522 | 1 | #7 of 11 | Jun 28, 2026 |
| RASolute 302 | 1 | #42 of 73 | Jun 27, 2026 |
| EV302 | 1 | #15 of 19 | Jun 27, 2026 |
| POTOMAC | 1 | #12 of 17 | Jun 27, 2026 |
| DeLLphi-304 | 1 | #22 of 23 | Jun 1, 2026 |
| IMforte | 1 | #7 of 12 | May 31, 2026 |
| LIBRETTO-432 | 1 | #22 of 53 | May 31, 2026 |
| OptiTROP-Lung05 | 1 | #11 of 19 | May 29, 2026 |
| WU-KONG28 | 1 | #12 of 29 | May 29, 2026 |
Chul Kim on HARMONi-6
Love the slide by Dr. Brahmer. VEGF blockade is back in fashion! Key questions remain for HARMONi-6: durability of OS benefit at final analysis, older-patient signal, and global generalizability. #ASCO26 https://t.co/ZjgUH8ukOE
RT @BalazsHalmosMD: HARMONI-6 study results brings music to an oncologist’s ears! Doublet chemo/ivonescimab vs chemo/tislelizumab shows cl…
RT @StephenVLiu: Dr. Shun Lu presents HARMONi-6 #ASCO26 plenary: first-line ivonescimab + chemo (carbo + pac) vs tislelizumab + chemo in sq…
Chul Kim on DESTINY-Lung04
HER2-mutant NSCLC: One of the most rapidly evolving fields! Three approved agents: zongertinib, sevabertinib, and T-DXd (first two now approved in 1L). DESTINY-Lung04 presented at #WCLC26. Ongoing randomized 1L trials will further reshape the landscape! @DDoroshow #DCLung26 https://t.co/3Om64OdZSv
HER2-mutant NSCLC landscape at #TTLC2026 by Dr. Christina Paik👇 In previously treated pts, three FDA approved drugs: T-DXd, Zongertinib, Sevabertinib. 1L phase 3 trials ongoing: DESTINY-Lung04, Beamion LUNG-2 m, SOHO-02. https://t.co/f9meok1tFL
Chul Kim on CROWN
Comprehensive overview of ALK fusion-positive NSCLC in 5 minutes by @Alfdoc2 #DCLung2026. Many excellent treatment options, but CROWN (lorlatinib vs. crizotinib) has passed the “truck test”! Novel agents like neladalkib and innovative approaches such as ALK vaccines emerging. https://t.co/Y8FHpgEKku
Seven-year follow-up of CROWN confirms the durability of first-line #lorlatinib in ALK+ NSCLC: 55% remain progression-free at 7 years, median PFS unreached, and intracranial control is unprecedented (HR for IC progression 0.06). A new benchmark in targeted therapy. #ASCO26 https://t.co/X1Vl4mTP53
Chul Kim on KEYNOTE-522
Dr. Katia Khoury reviewed key early breast cancer abstracts: SENOMAC suggests completion axillary dissection may be omitted in select patients with 1–2 SLN macrometastases, while KEYNOTE-522 and OASIS-4 add important updates in TNBC and survivorship. @TotalHealthConf #BestofASCO https://t.co/hCPUDFEfl9
Chul Kim on RASolute 302
Great discussion by Dr. Valerie Lee @Hopkins: RASolute 302 showed daraxonrasib improved OS/PFS/QoL vs chemo in previously treated RAS G12-mutant mPDAC. Key next steps: access, AE management, and defining roles in 1L/adjuvant settings. #BestofASCO26 @TotalHealthConf https://t.co/RaqdXRdbKX
Chul Kim on EV302
Dr. @MikeSerzanMD , former Georgetown fellow and now GU oncologist at Dana-Farber, expertly reviewed key non-prostate GU cancer abstracts from #ASCO26 at Best of ASCO DC, including POTOMAC and EV-302 updates! @TotalHealthConf https://t.co/HP5sxVif4y
Chul Kim on POTOMAC
Dr. @MikeSerzanMD , former Georgetown fellow and now GU oncologist at Dana-Farber, expertly reviewed key non-prostate GU cancer abstracts from #ASCO26 at Best of ASCO DC, including POTOMAC and EV-302 updates! @TotalHealthConf https://t.co/HP5sxVif4y
Chul Kim on DeLLphi-304
ASCO26 DeLLphi-304 CNS post hoc: #tarlatamab delayed CNS progression/death vs chemo in 2L ES-SCLC. CNS PFS HR 0.54 overall; HR 0.40 with brain mets. Also improved OS in pts with brain mets: 13.9 vs 6.8 mo; HR 0.51. Strong CNS signal here. https://t.co/W5KH4Wl1sd
Chul Kim’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Amivantamab + lazertinib achieved a median OS of 41.0 months in treatment-naïve atypical EGFR-mutant NSCLC, with no clear association between EGFR variant subtype and outcome. A compelling option. Meanwhile, amivantamab continues evaluation across multiple tumor types. #ASCO26 https://t.co/aWn3Ja60Ji
#ASCO26 ES-SCLC: Adding concurrent thoracic RT 30 Gy/10 fx to durvalumab + platinum/etoposide did not improve OS/PFS and increased AEs/TR deaths. Awaiting results from RAPTOR (NRG-LU007). https://t.co/NCYB7rH858
DLL3-targeted CAR-T LB2102 in R/R SCLC/LCNEC: phase 1 N=20 showed no DLTs or treatment -related deaths; CRS 30% all grade ≤2; ICANS 15%. At DL3+: ORR 28.6%, DCR 78.6%, median DOR 6.5 mo. Early but encouraging data! #ASCO26 https://t.co/G8m5vredd7
KRAS G12D development is active, with multiple approaches: OFF, ON/tri-complex, ON/OFF, degraders/PROTACs, pan-KRAS inhibitors Zoldonrasib/setidegrasib NSCLC and PDAC data suggest meaningful activity Durability, combinations,QoL remain key Great discussion by Dr. @KCArbourMD https://t.co/bC0QhwQN4M
Sunvozertinib improved PFS (10.3 vs 7.5 months; HR 0.65), ORR (58.9% vs 31.1%), and PFS2 (21.7 vs 15.5 months; HR 0.70) versus platinum doublet chemotherapy in EGFR exon20ins NSCLC. This will become an important treatment option in this space. #ASCO26 https://t.co/uam5geHn0p
Industry Payments
CMS Open Payments · 2025 general payments
$64,694 across 72 payments